Publications by authors named "Jairo Bada Da Silva"
Article Synopsis
- Hyperkalaemia is a common electrolyte imbalance in chronic kidney disease (CKD) patients, with varying prevalence among different treatment groups: 9.6% in CKD patients not on dialysis, 16.4% in those undergoing haemodialysis, and 10.6% in those on peritoneal dialysis.
- Factors associated with hyperkalaemia include decreased kidney function (measured as GFR), higher plasma creatinine levels, and the use of RAAS inhibitors, particularly in patients with diabetes or heart failure.
- New treatments that can help lower potassium levels by binding it in the gut may help CKD patients continue to benefit from RAASi without the risk of hyperkalaemia.
Patients with chronic kidney disease (CKD) develop bleeding and thrombotic tendencies, so the indication of anticoagulation at the onset of atrial fibrillation (AF) is complex. AF is the most common chronic cardiac arrhythmia, and thromboembolism and ischemic stroke in particular are major complications. In recent years, new oral anticoagulant drugs have been developed, and they have shown superiority over the classical AVK in preventing stroke, systemic embolism and bleeding risk, constituting an effective alternative to those resources.
View Article and Find Full Text PDF